HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company. The final size and terms are subject to market conditions, according to the press release.
The company intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities, and support working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as sole bookrunner for the offering.
HeartBeam is developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology enablement.
For more details, the full press release is available at https://ibn.fm/pxFOz. Investors can find the latest news and updates at the company’s newsroom at https://ibn.fm/BEAT. The cleared indications for use are detailed at https://www.heartbeam.com/indications.
This offering marks a critical step for HeartBeam as it seeks to scale its innovative cardiac monitoring technology and integrate artificial intelligence into its platform. The capital raised will support ongoing research and development, as well as commercialization efforts that could expand access to advanced ECG monitoring outside traditional clinical settings.
